These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Soluble interleukin-2 receptor levels in cerebrospinal fluid of patients with acute lymphocytic leukemia or with non-Hodgkin's lymphoma.
    Author: Chang CS, Liu HW, Lin SF, Chen TP.
    Journal: Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1989 May; 22(2):132-7. PubMed ID: 2605973.
    Abstract:
    An elevated serum soluble interleukin-2 receptor (SIL-2R) has been noted in various hematological malignancies and conditions associated with active T-cell responses. Its appearance has also correlated with disease activity and tumor burden. Since few studies have been reported concerning SIL-2R in cerebrospinal fluid (CSF), work was undertaken to try to find if SIL-2R could be detected in the CSF of patients with acute lymphocytic leukemia (ALL) or non-Hodgkin's lymphoma (NHL), and whether it could become a clinical predictor of the central nervous system (CNS) involvement, and its response to therapy. Preliminary results showed that 1) the CSF SIL-2R is usually detectable in very low level with a mean of 15.1 +/- 14.2 units/ml compared with the mean serum level of 338.3 +/- 135.5 units/ml in eight normal controls; 2) there was no significant difference in the mean serum and CSF SIL-2R in five patients with ALL in a complete remission state compared with normal controls, while two ALL patients with CNS relapse and two NHL patients with CNS involvement had high levels of SIL-2R in CSF. High serum and low CSF SIL-2R levels were noted in another ALL case suffering from bone marrow relapse but without CNS relapse. It was also noted that decreased CSF SIL-2R concentration occurred subsequent to intrathecal chemotherapy in two ALL patients. From these results, we conclude that CSF SIL-2R might become a useful indicator of CNS involvement in patients with hematological malignancies and may predict response to chemotherapy.
    [Abstract] [Full Text] [Related] [New Search]